Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
topic_facet:"610"
topic_facet:"Phase: Phase 2"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22610%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22610%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22610%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
PubPharm (1.210)
1
Study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemia : Randomised phase II/III study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemia - RAINBOW
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
A study investigating Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the treatment of patients with Myasthenia Gravis, dependent on Corticosteroids. The patients will receive 2g/kg of IP as a loading dose. The loading dosage is followed by maintenance doses of 1 g/kg administered every third week until Visit 13 (Week 36). During maintenance doses the investigator will try to slowly reduce the patient's corticosteroid dose. : A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ chromatography Purified (lGIV -C) as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients with Generalized Myasthenia Gravis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
Study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemia : Randomised phase II/III study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemia - RAINBOW
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
A study investigating Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the treatment of patients with Myasthenia Gravis, dependent on Corticosteroids. The patients will receive 2g/kg of IP as a loading dose. The loading dosage is followed by maintenance doses of 1 g/kg administered every third week until Visit 13 (Week 36). During maintenance doses the investigator will try to slowly reduce the patient's corticosteroid dose. : A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ chromatography Purified (lGIV -C) as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients with Generalized Myasthenia Gravis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF A MONTELUKAST INHALED CORTICOSTEROID COMPARED TO THERAPY WITH A INHALED CORTICOSTEROID ONLY, IN PATIENTS WITH CHRONIC ASTHMA : RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF A MONTELUKAST INHALED CORTICOSTEROID COMPARED TO THERAPY WITH A INHALED CORTICOSTEROID ONLY, IN PATIENTS WITH CHRONIC ASTHMA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
A DOSE-RANGING STUDY OF VILANTEROL (VI) INHALATION POWDER IN CHILDREN AGED 5-11 YEARS WITH ASTHMA ON A BACKGROUND OF INHALED CORTICOSTEROID THERAPY : A DOSE-RANGING STUDY OF VILANTEROL (VI) INHALATION POWDER IN CHILDREN AGED 5-11 YEARS WITH ASTHMA ON A BACKGROUND OF INHALED CORTICOSTEROID THERAPY
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
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
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
10
A PHASE IIA, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF MTP9579AIN PATIENTS WITH ASTHMA REQUIRING INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER. : A PHASE IIA, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF MTP9579A IN PATIENTS WITH ASTHMA REQUIRING INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[121]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Filter aufheben
Thema: 610
Filter aufheben
Thema: Phase: Phase 2
Medienart
1.210
Aufsätze
1.210
E-Artikel
1.210
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
610
Phase: Phase 2
1.194
Study Type: Interventional
614
Recruitment Status: Not yet recruiting
276
Recruitment Status: Authorised-recruitment may ...
122
Recruitment Status: Recruiting
64
Recruitment Status: Completed
62
Recruitment Status: Complete: follow-up complete
42
Medical Condition: Multiple Myeloma MedDRA vers...
22
Medical Condition: ;Neoplasms
22
Medical Condition: Chronic obstructive pulmonar...
20
Medical Condition: Asthma MedDRA version: 14.0L...
20
Medical Condition: Moderate to Severe Ulcerativ...
20
Recruitment Status: Complete: follow-up continuing
18
Medical Condition: Asthma MedDRA version: 18.1L...
16
Medical Condition: Multiple Myeloma; Multiple M...
16
Medical Condition: multiple myeloma
14
Medical Condition: ;Diseases of the blood and b...
14
Medical Condition: Moderate or severe cGVHD Med...
14
Medical Condition: Multiple Myeloma MedDRA vers...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
798
2020-
412
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
1.200
Englisch
6
Unbestimmt
4
Französisch
Haven't found what you're looking for?
Wird geladen...